Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02581657
• Other study ID #: PE0139-PT-CL-0002
• Status: Completed
• Phase: Phase 2
• First received: October 9, 2015
• Last updated: April 6, 2018
• Start date: October 2015
• Est. completion date: November 2016

Study information

• Verified date: April 2018
• Source: PhaseBio Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM) in up to four cohorts.

Description:

This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with T2DM in up to four cohorts; (6 active/2 placebo subjects in cohort 1, and up to 9 active/4 placebo in each subsequent cohort).

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic response of PE0139 in the presence of existing stable non-insulin antidiabetic background therapy. Subjects will return weekly for a total of 6 doses of study drug.

Study remains active, not recruiting as subjects who received active study drug will be followed for secondary outcome measures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Willing and able to sign a written informed consent and follow all study-related procedures;

• Male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study drug;

• Body mass index = 18 kg/m2 and = 45 kg/m2;

• Diagnosed with T2DM with HbA1c of = 7.5% and <11.0% and who is currently taking a non-insulin antidiabetic therapy at stable dose(s) for 3 months prior to screening;

• Willing and able to comply with all study procedures including wearing a continuous glucose monitoring device and performance of frequent self-monitored blood glucose profiles according to the protocol;

• Minimum 7-day average daily glucose of 154 mg/dL (based on CGM) at baseline evaluation;

• Willing to refrain from taking acetaminophen (paracetamol) containing products (e.g., Tylenol®) 24 hours prior to the placement of the CGM device and throughout the time period when the CGM device is worn;

• Live and work in an area with reliable Verizon cellular service for transmission of glucose data required for use of the Telcare Glucose Monitoring System.

Exclusion Criteria:

• Clinical diagnosis of Type 1 diabetes;

• Currently taking or have routinely taken, within 6 months prior to screening, a long or short-acting insulin;

• Self-reported significant change in weight defined as either a loss or gain = 10% during the three month period prior to screening or between screening and randomization;

• Known allergy to, or serious adverse effect caused by an approved, or investigational insulin product or any of its components;

• Currently taking any of the following medications: thiazide or furosemide diuretics, beta-blockers, estrogens or other hormonal replacement therapy, or other chronic medications with known adverse effects on glucose tolerance levels unless the subject has been on stable doses of such agents for at least 2 months prior to screening and have no planned changes in concomitant medication usage during the study period;

• Self-reported history of severe hypoglycemia or hypoglycemic unawareness, as judged by the Investigator;

• Self-reported history of acute complications secondary to diabetes within the last 6 months prior to screening or signs or symptoms of clinically significant diabetes related complications prior to screening;

• Malignant disease defined as: Self-reported history of malignant melanoma or breast cancer; Self-reported history of other types of cancer (excludes basal/squamous cell carcinoma or cervical carcinoma if treated and condition not currently active) within the last 5 years prior to screening;

• Unstable cardiovascular disease defined as one or more of the following: Self-reported history of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to screening; Self-reported history of or currently have NYHA Class III-IV heart failure prior to screening; Self-reported history of unstable angina within 3 months prior to screening; Uncontrolled/sustained hypertension; Self-reported history of clinically significant ECG abnormalities or evidence of clinically significant ECG abnormalities;

• Clinically significant renal and/or hepatic dysfunction noted on safety labs;

• Absolute requirement for corticosteroids or have routinely received systemic steroids within 12 months prior to randomization or use of inhaled corticosteroids within 1 month prior to randomization. A single short course treatment of systemic steroids to treat an acute infection will not exclude the subject if taken more than 3 months from screening;

• Pregnant or lactating female subjects;

• Known history of alcohol abuse or use of illicit drugs within 1 year prior to screening, and/or who test positive for alcohol and illicit drugs prior to randomization. Note: A subject will be considered in violation of the study if they test positive prior to any planned dosing and will be discontinued from the study;

• Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies at screening;

• Previously received PE0139;

• Participating in any other study and have received any other investigational medication or device within 30 days prior to screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with the outcome of the study;

• Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk or would preclude obtaining voluntary consent or would confound the secondary objectives of the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• PE0139 Injection
PE0139 Injection
• Placebo Injection
Placebo Injection

Locations

Country	Name	City	State
United States	Pinnacle Research Group, LLC	Anniston	Alabama
United States	Meridien Research	Bradenton	Florida
United States	Indago Research and Health Center, Inc.	Hialeah	Florida
United States	National Research Institute	Huntington Park	California
United States	New Orleans Center for Clinical Research	New Orleans	Louisiana
United States	Rainier Clinical Research	Renton	Washington

Sponsors (1)

Lead Sponsor	Collaborator
PhaseBio Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability (as assessed by incidence and severity of adverse events (AEs), hypoglycemia and changes from baseline in vital signs, ECGs and safety laboratory parameters).	To evaluate the safety and tolerability (as assessed by incidence and severity of AEs, hypoglycemia and changes from baseline in vital signs, ECGs and safety laboratory parameters) of multiple ascending doses of PE0139 administered as once weekly injection for 6 weeks in adults with T2DM.	AEs and hypoglycemia (Day -60 to 63), Vital signs (Days -60, -10, 0, 7, 14, 21, 28, 35, 42, 49 and 63), safety laboratory parameters (-60, -10, 14, 28, 42, 49 (as needed), and 63) ECGs (-60, -10, 14, 28, 42, 49 (as needed) and 63).
Secondary	Pharmacokinetic (PK) profile - Area under the curve over the dosing interval (AUC (0-t))	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacokinetic (PK) profile - Area under the curve concentration-time profile from 0 to Tmax [AUC (0-tmax)] and from Tmax to t [AUC(tmax-t]	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacokinetic (PK) profile - Maximum serum concentration (Cmax)	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacokinetic (PK) profile - Time to Cmax (Tmax)	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacokinetic (PK) profile - Elimination Rate Constant (Lamda z)	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacokinetic (PK) profile - Elimination half-life (t1/2)	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacokinetic (PK) profile - Clearance (CL/F), uncorrected for bioavailability	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacokinetic (PK) profile - Volume of Distribution (Vz/F), uncorrected for bioavailability	Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.	PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose).
Secondary	Pharmacodynamic (PD) Profile - Change from baseline in fasting plasma glucose	Characterize the PD response of various doses of PE0139 and glucose (as assessed by fasting and non-fasting plasma glucose)	PD response measured as fasting plasma glucose (FPG) (daily by subject up to day 21 and Days -60, between days -10 and -7, 0, 1-7, 14, 21, 28, 35, 36-49 and 63 at CRU)
Secondary	Pharmacodynamic (PD) Profile - Change from baseline in average glucose by CGM	Characterize the PD response of various doses of PE0139 and glucose (as assessed by CGM)	PD response measured by continuous glucose monitoring (CGM) (baseline collected =7 days pre-dose daily after dose 3 for 4 weeks)
Secondary	Fructosamine changes	Assess the effect of various doses of PE0139 on change in fructosamine following 6 weeks of repeat, once-weekly dosing.	Measured at pre-dose and 7 days after last dose
Secondary	Required dose adjustment to background therapy	Assess the incidence for required dose adjustment to background therapy across various doses of PE0139 and compared to placebo.	All scheduled and unscheduled visits (Days -60 to 63)
Secondary	Reported hypoglycemic events (% of subjects experiencing severe and non-severe hypoglycemic events)	Describe incidence, severity, and duration of reported hypoglycemic events across various doses of PE0139 and compared to placebo. Reported as % of subjects experiencing a hypoglycemic event (severe (requiring medical assistance or =36 mg/dL glucose) or non-severe (not requiring medical assistance and <70mg/dL glucose))	All scheduled and unscheduled visits (Days -60 to 63)
Secondary	Binding anti-drug antibodies to PE0139 and insulin (as needed). If positive, neutralizing activity will also be assessed.	Characterize the immunogenicity profile (binding drug antibodies to PE0139 and insulin (as needed) and neutralizing antibodies if noted to be positive) following 6 weeks of repeat, once-weekly dosing.	Collected at Pre-dose, Days 7, 14, 21, 28, 35, 42, 49, 63 and 91.